On Tuesday, Pfizer (PFE) said it will enter the direct-to-consumer business, following the lead of a Big Pharma rival, Eli ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Amazon Pharmacy will provide dispensing for Eli Lilly’s recently launched LillyDirect service, a direct-to-consumer (DTC) telehealth channel that has caused a stir in the US market. Under the ...

PfizerForAll has similarities with Eli Lilly's LillyDirect DTC service ... whilst opening up direct communication with patients and making it easier for them to source treatments.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

Fortunately, that's starting to change. In recent months, drug companies Pfizer and Eli Lilly have begun rolling out direct-to-consumer programs that let patients purchase basic prescriptions ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

The company is now offering 2.5-milligram and 5-milligram single-dose vials of Zepbound for $399 per month and $549 per month ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...